NEW BRUNSWICK, N.J.,
May 17, 2017 /PRNewswire/ -- At a
meeting today with industry analysts, senior leaders of Johnson
& Johnson (NYSE: JNJ) and its Janssen Pharmaceutical
Companies will announce plans to launch or file for regulatory
approval more than 10 new products with blockbuster potential
between 2017 and 2021, as well as 50-plus line extensions of
existing and new medicines that will bring the company's
transformational medicines to an even broader patient population.
The company will also share its plans to continue driving
sustainable growth by leveraging its strong portfolio of core
blockbuster products, the industry-leading productivity of its
innovation model, and the pending acquisition of Swiss-based
biotech company Actelion.
"With a growing core business of differentiated medicines and a
strong line-up of innovative products expected to launch or file
over the next five years, we are leading the industry in advancing
the health of patients around the world," said Alex Gorsky, Chairman and Chief Executive
Officer. "Our pharmaceutical business will continue to be a
significant driver of innovation and growth for Johnson &
Johnson. With our proven global commercial capabilities and robust
pipeline, we are well-positioned to continue delivering strong,
long-term, sustainable growth."
An industry leader in research productivity, Janssen has
received US FDA approval for 11 new molecular entities (NMEs) since
2011. With a portfolio focused on five core therapeutic areas –
Immunology, Infectious Diseases & Vaccines, Neuroscience,
Cardiovascular & Metabolism, and Oncology – the Pharmaceutical
segment of Johnson & Johnson is delivering transformational new
medicines for unmet medical needs worldwide, and expects to add a
sixth therapeutic area in Pulmonary Arterial Hypertension upon the
completion of the acquisition of Actelion, which is expected to
close by the end of the second quarter.
In 2016, the company filed two NMEs that it anticipates will be
approved and launched later this year:
- guselkumab for psoriasis; and
- sirukumab for rheumatoid arthritis.
Additional late-stage blockbuster products1 projected
to file for regulatory approvals between 2017 and 2021,
include:
- apalutamide (ARN-509) for pre-metastatic prostate cancer;
- esketamine for treatment-resistant depression;
- talacotuzumab (CSL362) for acute myeloid leukemia;
- erdafitinib (FGFR Inhibitor) for solid tumors;
- niraparib for prostate cancer;
- imetelstat for myelofibrosis;
- pimodivir (JNJ-3872) for influenza A;
- lumicitabine (JNJ-1575) for respiratory syncytial virus (RSV)
infection; and,
- JNJ-7922 (orexin-2 antagonist) for adjunctive treatment for
major depressive disorder.
About Today's Meeting
The meeting will be webcast starting at 8:30 a.m. EDT today and can be accessed along
with full copies of the presentations and speaker biographies via
the Johnson & Johnson Investor Relations website:
www.investor.jnj.com. A replay and podcast will be available
shortly after the live webcast. A live Twitter feed for today's
meeting is accessible via #PBR17JNJ.
Users of the Johnson & Johnson Investor Relations mobile app
for the iPad® and iPhone® mobile digital devices can also access
the event. This free app is available in the iTunes® store and
includes stock information, news releases, company information,
webcasts, SEC filings, the company's pharmaceutical product
pipeline and Annual Reports, among other information.
About Johnson & Johnson
Caring for the world, one person at a time…inspires and unites
the people of Johnson & Johnson. We embrace research and
science – bringing innovative ideas, products and services to
advance the health and well-being of people. Our approximately
130,800 employees at more than 250 Johnson & Johnson operating
companies work with partners in health care to touch the lives of
over a billion people every day, throughout the world.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as
defined in the Private Securities Litigation Reform Act of 1995
regarding, among other things, future operating and financial
performance, product research and development, regulatory
submissions and approvals, market position, impact of planned
acquisitions, and business strategy. The viewer is cautioned not to
rely on these forward-looking statements. These statements are
based on current expectations of future events. If underlying
assumptions prove inaccurate or known or unknown risks or
uncertainties materialize, actual results could vary materially
from the expectations and projections of the Janssen Pharmaceutical
Companies and/or Johnson & Johnson. Risks and uncertainties
include, but are not limited to: challenges and uncertainties
inherent in new product research and development, including
uncertainty of clinical success and decisions of regulatory
authorities regarding approval, labeling, and other matters that
could affect the availability or commercial potential of product
candidates; uncertainty of commercial success for new and existing
products; the satisfaction of closing conditions for the
acquisition of Actelion Ltd., the possibility that the Actelion
acquisition will not be completed in the expected timeframe or at
all, and the potential that the expected benefits and opportunities
of the Actelion acquisition, if completed, may not be realized or
may take longer to realize than expected; the ability of the
company to successfully execute strategic plans; challenges to
patents; the impact of patent expirations; competition, including
technological advances, new products, and patents attained by
competitors; future clinical data and analysis, including post
marketing surveillance; impact of business combinations and
divestitures; significant adverse litigation or government action;
changes to applicable laws and regulations, including global health
care reforms; trends toward health care cost containment; changes
in behavior and spending patterns of purchasers of health care
products; manufacturing difficulties or delays; product efficacy or
safety concerns resulting in product recalls or regulatory action;
and increased scrutiny of the health care industry by government
agencies. A further list and descriptions of these risks,
uncertainties, and other factors can be found in Johnson &
Johnson's Annual Report on Form 10-K for the fiscal year ended
January 1, 2017, including in the
sections captioned "Cautionary Note Regarding Forward-Looking
Statements" and "Item 1A. Risk Factors," and the company's
subsequent filings with the Securities and Exchange Commission.
Copies of these filings are available online at www.sec.gov,
www.investor.jnj.com, or on request from Johnson & Johnson. Any
forward-looking statement made in this release speaks only as of
the date of these release. Johnson & Johnson does not undertake
to update any forward-looking statement as a result of new
information or future events or developments.
iPad, iPhone and iTunes are trademarks of Apple Inc.
1 Many of these products are being developed in
collaboration with strategic partners or are licensed from other
companies; see webcast presentation for more information.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/johnson--johnson-showcases-strong-pipeline-of-transformational-medicines-at-its-pharmaceutical-business-review-meeting-300458974.html
SOURCE Johnson & Johnson